PRME
Prime Medicine, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$501.21M
P/E Ratio
—
EPS
$-1.23
Beta
2.31
52W High
$6.94
52W Low
$1.41
50-Day MA
$3.33
200-Day MA
$3.96
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc. is a leading biotechnology company pioneering advancements in genetic medicine through its proprietary Prime Editing technology, which facilitates precise DNA modifications. The company has developed a robust pipeline aimed at addressing severe diseases, including genetic disorders and various cancers, positioning it to meet substantial unmet medical needs. With a strong foundation of intellectual property and a clear vision for transformative therapeutic solutions, Prime Medicine is positioned for significant growth, potentially redefining treatment paradigms within the biopharmaceutical landscape.
Fundamentals
| Revenue (TTM) | $4.03M |
| Gross Profit (TTM) | $-150.14M |
| EBITDA | $-199.14M |
| Operating Margin | -5918.00% |
| Return on Equity | -216.10% |
| Return on Assets | -41.50% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.42 |
| Price-to-Book | 6.64 |
| Price-to-Sales (TTM) | 124.25 |
| EV/Revenue | 121.06 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -41.10% |
| Shares Outstanding | $180.62M |
| Float | $108.73M |
| % Insiders | 23.76% |
| % Institutions | 66.62% |
Historical Volatility
HV 10-Day
95.81%
HV 20-Day
91.89%
HV 30-Day
81.42%
HV 60-Day
71.78%
HV Rank
31.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.92 target)
1
Strong Buy8
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026